The objective of the current study is to investigate the utilization of nebulized heparin to circumvent pathologic changes in COVID-19 and prevent harmful effects possible with systemic anticoagulation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
2
UK Healthcare
Lexington, Kentucky, United States
Mean PaO2/FiO2 Ratio
Time frame: Within the first 10 days of ICU stay or up until ICU discharge, whichever occurs first
Clinically Significant Bleeding
Time frame: Up to discharge or 3 months following enrollment, whichever occurs first
Incidence of Venous Thromboembolism
Time frame: Up to discharge or 3 months following enrollment, whichever occurs first
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.